NCT06519669View on ClinicalTrials.gov

Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients with Advanced Lung Cancer

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 18, 2024

Primary Completion Date

July 18, 2027

Study Completion Date

July 18, 2027

Conditions
AdultLung Cancer
Interventions
BIOLOGICAL

GT201 injection

GT201 injection to treat Advanced lung cancer

Trial Locations (2)

102200

RECRUITING

Beijing GoBroad Hospital, Beijing

200127

RECRUITING

Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

Sponsors

Lead Sponsor

Grit Biotechnology
All Listed Sponsors
lead

Grit Biotechnology

INDUSTRY

NCT06519669 - Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients with Advanced Lung Cancer | Biotech Hunter | Biotech Hunter